ZYBERNO
Stock Report
Updated Sep 1, 2026

MATINAS BIOPHARMA HOLDINGS, INC. (MTNB)

Healthcare • NYSE

$0.19

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
8.0/100
POOR BUSINESS
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) scores 8/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-166.1%)
Debt-to-Equity (Solvency Risk):AVERAGE (0.66x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-476.7%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) stock report — Zyberno Score 8/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.19
Market Cap:$1.25M

Valuation Multiples (2)

P/B Ratio:0.69x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$496.29K

Price Action & Momentum (1)

% of 52-Week High:9.1%
B. Profitability Assessment

Return Metrics (5)

ROA:-102.2%
Reinvestment Rate:41.3%
Fundamental Growth Rate (g):-196.8%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$491.45
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:76.2%
Latest Earnings Filed:2026-08-13
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.85x
Quick Ratio:0.85x
Cash Ratio:0.56x

Leverage Analysis (3)

Debt To Equity Ttm:0.66x
Debt-to-Equity Ratio:0.66x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:-207,000.00
Cash And Cash Equivalents:761,000.00
Long Term Debt:$6.00K
Net Debt:-$751.00K
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$6.67M

Bottom Line Performance (3)

-$6.69M
Income Before Tax:-$10.35M
Ebitda Ttm:-6,654,000.00

Operating Expenses (5)

Operating Expenses:6,668,000.00
R And D Expense:85,000.00
Sga Expense:6,668,000.00
Income Tax Expense:$1.00M
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$3.41M
Current Assets:$1.14M
Ppe Net:138,000.00
Goodwill:1,336,000.00
Intangible Assets:$2.26M

Liability Structure (4)

Total Liabilities:1,612,000.00
Current Liabilities:1,350,000.00
Long Term Debt:$6.00K
Short Term Debt:$4.00K

Equity & Capital (3)

Equity:$1.80M
Retained Earnings:-$214.03M
Common Stock:500,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:845,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:104,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$6.61M$0.00

Investment Activities (1)

Investing Cash Flow:$15.00K

Financing Activities (3)

Financing Cash Flow:$58.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:9,179,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:14,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.15
-$1.15
Earnings Per Share Ttm:-$1.04

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$1.09

Book Value & Capital (2)

Book Value Per Share:$0.28
Cash Per Share:0.12

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:41.3%
Fundamental Growth Rate (g):-196.8%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-50.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:MTNB
Company Name:MATINAS BIOPHARMA HOLDINGS, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NYSE
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:6.41M
Shares Outstanding Basic:6.41M
Shares Outstanding Diluted:6.41M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 18:42:50 UTC
Data Timestamp:2026-08-22T04:35:13.852345
Scroll to Top